Prakash Achaary

Posted June 7, 2017
Emmaus Life Sciences Inc. (Emmaus) has announced that EndariTM for the treatment of sickle cell disease (SCD) has been recommended for approval by the Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee. In a10–3 vote, the committee recognized that the overall benefit-risk profile of disease was favorable. MMS Holdings Inc. (MMS) has been providing clinical data, writing and regulatory submission support for Emmaus since 2015.

Posted March 14, 2016
MMS Holdings Inc., a specialty data-focused CRO, has announced a $1M award toward the development of a Zika vaccine. The award is being offered as data services to qualified pharmaceutical companies supporting the commercial development of a vaccine for approval in the United States and/or other global regulatory markets.

HYDERABAD (January 26, 2016) — MMS Holdings Inc. (www.mmsholdings.com) is pleased to announce the opening of a new office in Hyderabad, India. The company’s Asia headquarters are located in Bangalore, India and the company’s ability to deliver exceptional quality across all of its service offerings has resulted in steady growth for the company. According to Prasad … MMS Announces Expansion of Asia Operations In Hyderabad

Posted June 11, 2014
MMS Holdings Inc., a clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries, and the Wayne State University (WSU) Graduate School announced today the creation of a scientific internship program to broaden career opportunities for graduate students.

Posted August 1, 2013
MMS Holdings Inc. today announced that it has been selected to partner with Knopp Biosciences to provide best-in-class pharmacovigilance services in support of their compound, dexpramipexole.